161 related articles for article (PubMed ID: 29124666)
1. Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.
Mazzaglia G; Straus SMJ; Arlett P; da Silva D; Janssen H; Raine J; Alteri E
Drug Saf; 2018 Feb; 41(2):191-202. PubMed ID: 29124666
[TBL] [Abstract][Full Text] [Related]
2. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
Farcas A; Huruba M; Mogosan C
Br J Clin Pharmacol; 2019 Mar; 85(3):476-491. PubMed ID: 30497102
[TBL] [Abstract][Full Text] [Related]
3. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
Vora P; Artime E; Soriano-Gabarró M; Qizilbash N; Singh V; Asiimwe A
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):695-706. PubMed ID: 29663572
[TBL] [Abstract][Full Text] [Related]
4. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.
Grupstra RJ; Goedecke T; Scheffers J; Strassmann V; Gardarsdottir H
Clin Pharmacol Ther; 2023 Dec; 114(6):1285-1292. PubMed ID: 37634124
[TBL] [Abstract][Full Text] [Related]
5. Are risk minimization measures for approved drugs in Europe effective? A systematic review.
Artime E; Qizilbash N; Garrido-Estepa M; Vora P; Soriano-Gabarró M; Asiimwe A; Pocock S
Expert Opin Drug Saf; 2019 May; 18(5):443-454. PubMed ID: 31032651
[No Abstract] [Full Text] [Related]
6. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
7. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.
Smith MY; Russell A; Bahri P; Mol PGM; Frise S; Freeman E; Morrato EH
Drug Saf; 2018 Apr; 41(4):389-401. PubMed ID: 29218682
[TBL] [Abstract][Full Text] [Related]
8. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
[TBL] [Abstract][Full Text] [Related]
9. Three years of paediatric regulation in the European Union.
Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine drug utilization study in five European countries: A multinational, retrospective, observational study to assess effectiveness of risk-minimization measures.
Salem L; Malouvier A; Blatchford J; Rivero-Ferrer E; Deltour N; Jacquot E
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1470-1479. PubMed ID: 31486198
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
12. Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review.
Russell AM; Morrato EH; Lovett RM; Smith MY
Drug Saf; 2020 May; 43(5):427-446. PubMed ID: 32020558
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
[TBL] [Abstract][Full Text] [Related]
14. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
16. Patient Preferences for Rituximab Additional Risk Minimization Measures: Results From an International Online Survey.
Schneiderova K; Bere N; Stenver DI; Straus SMJM
J Patient Saf; 2022 Jun; 18(4):331-336. PubMed ID: 34608891
[TBL] [Abstract][Full Text] [Related]
17. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
19. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
20. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
Carleer J; Karres J
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
